Scarica l'app Stockscreener
39.77
4.01%
-1.66
Precedente Chiudi:
$41.43
Aprire:
$40.86
Volume 24 ore:
436.66K
Relative Volume:
1.09
Capitalizzazione di mercato:
$1.91B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-5.53%
1M Prestazione:
+6.71%
6M Prestazione:
+235.33%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$38.13
$41.83
Intervallo di 1 settimana:
$38.13
$41.83
Portata 52W:
$6.71
$43.29
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Confronta MAZE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
39.77 | 1.99B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Iniziato | Wells Fargo | Overweight |
| 2025-11-14 | Iniziato | Raymond James | Outperform |
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9%Here's Why - MarketBeat
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Atul Dandekar Sells 72,400 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $2,936,544.00 in Stock - MarketBeat
Maze Therapeutics SVP, finance sells $606k in shares - Investing.com
Maze Therapeutics Insider Sold Shares Worth $1,825,355, According to a Recent SEC Filing - marketscreener.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Growth Recap: Is Maze Therapeutics Inc stock trading at a premium valuationEarnings Overview Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
How Maze Therapeutics Inc. stock benefits from tech adoptionMACD Histogram Signals & Free Fast Track Wealth Growth - bollywoodhelpline.com
New way to pay for at‑home AI neurorehab aims to widen access - Stock Titan
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
FY2025 Earnings Estimate for MAZE Issued By Lifesci Capital - MarketBeat
Maze Therapeutics price target raised to $46 from $34 at Guggenheim - MSN
Fundamentals Check: How Maze Therapeutics Inc. stock benefits from tech adoptionWeekly Stock Recap & Expert Approved Trade Ideas - Улправда
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Lifesci Capital - Defense World
Guggenheim Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program - Investing.com Canada
What sentiment indicators say about Maze Therapeutics Inc. stockEarnings Risk Summary & Community Shared Stock Ideas - DonanımHaber
Lifesci Capital Upgrades Maze Therapeutics (NASDAQ:MAZE) to Strong-Buy - MarketBeat
What dividend safety score for Maze Therapeutics Inc. stockWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study - Investing.com Canada
We're Not Worried About Maze Therapeutics' (NASDAQ:MAZE) Cash Burn - Sahm
Frazier Life Sciences Management L.P. Buys 438,274 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics - Yahoo Finance
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Wall Street Zen - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.2%Time to Sell? - MarketBeat
CW Advisors LLC Purchases Shares of 30,235 Maze Therapeutics, Inc. $MAZE - MarketBeat
Investment Report: How Maze Therapeutics Inc stock benefits from tech adoptionJuly 2025 Market Mood & Accurate Buy Signal Alerts - BỘ NỘI VỤ
Maze Therapeutics (MAZE) Price Target Increased by 11.37% to 44.12 - Nasdaq
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wells Fargo Initiates Coverage of Maze Therapeutics (MAZE) with Overweight Recommendation - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week HighTime to Buy? - MarketBeat
Maze Therapeutics stock price target raised to $60 from $50 at H.C. Wainwright - Investing.com Canada
A significant driver of top-line growth: Maze Therapeutics Inc (MAZE) - setenews.com
MAZE Crosses Above Average Analyst Target - Nasdaq
Maze Therapeutics stock rating initiated at Overweight by Wells Fargo - Investing.com Canada
HC Wainwright & Co. Maintains Maze Therapeutics (MAZE) Buy Recommendation - Nasdaq
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026, driving major growth - TradingView
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026 - TradingView
Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE - MarketBeat
Ensign Peak Advisors Inc Buys Shares of 18,539 Maze Therapeutics, Inc. $MAZE - Defense World
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Technical Analysis of Maze Therapeutics, Inc. (NASDAQ:MAZE) - TradingView
Will Maze Therapeutics Inc. stock sustain high P E ratiosTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Will Maze Therapeutics Inc. stock benefit from commodity pricesAnalyst Upgrade & Verified Swing Trading Watchlists - newser.com
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 8.4%Should You Buy? - MarketBeat
Price action breakdown for Maze Therapeutics Inc.2025 Stock Rankings & High Yield Equity Trading Tips - newser.com
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Non sono disponibili dati finanziari per Maze Therapeutics Inc (MAZE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Maze Therapeutics Inc Azioni (MAZE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dandekar Atul | CSBO |
Dec 30 '25 |
Option Exercise |
10.42 |
100 |
1,042 |
10,603 |
| Dandekar Atul | CSBO |
Dec 29 '25 |
Sale |
40.56 |
72,400 |
2,936,763 |
10,503 |
| Dandekar Atul | CSBO |
Dec 30 '25 |
Sale |
40.36 |
100 |
4,036 |
10,503 |
| Bernstein Harold | President, R&D & CMO |
Dec 29 '25 |
Option Exercise |
10.42 |
45,000 |
468,900 |
45,000 |
| Bernstein Harold | President, R&D & CMO |
Dec 29 '25 |
Sale |
40.56 |
45,000 |
1,825,355 |
0 |
| Bachrodt Amy | SVP, Finance |
Dec 29 '25 |
Option Exercise |
10.42 |
10,000 |
104,200 |
22,965 |
| Bachrodt Amy | SVP, Finance |
Dec 30 '25 |
Option Exercise |
10.42 |
5,000 |
52,100 |
17,965 |
| Bachrodt Amy | SVP, Finance |
Dec 29 '25 |
Sale |
40.58 |
10,000 |
405,766 |
12,965 |
| Bachrodt Amy | SVP, Finance |
Dec 30 '25 |
Sale |
40.08 |
5,000 |
200,407 |
12,965 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):